Red light for blue oxy: US FDA rejects Rexista's anti-abuse traits

By Flora Southey

- Last updated on GMT

Red light for blue oxy: US FDA rejects Rexista's anti-abuse traits

Related tags Opioid Morphine Codeine

The US FDA has rejected Intellipharmaceutics’ oxycodone product Rexista, raising concerns about the efficacy of its anti-abuse measures. 

In the complete response letter (CRL), the US Food and Drug Administration (FDA) requested further information on how the oxycodone hydrochloride extended-release tablets – in oral and nasal routes of administration – deters abuse, via Category 2 and Category 3 studies.

“We had already planned the additional Category 2 and Category 3 studies the FDA has requested and we do not expect they will impact our anticipated commercialisation timeline for Oxycodone ER,” ​said CEO Isa Odidi.

The CRL also requested further information regarding the blue dye in the formulation, designed to deter abuse, and asked the firm submit an alternate name for the product.

According to Intellipharmaceutics, the abuse-deterrent properties of Rexista are designed to discourage abuse or misuse via common routes of administration, including licking or crushing, inhalation, injection and ingestion after chewing.

“If approved, Rexista may be the only abuse-deterrent oxycodone product with properties that may provide early warning of drug abuse if the product is manipulated or abused,” ​said the firm.

The company said has one year to respond to the CRL, and plans to pursue the application in conjunction with the FDA.

“We will continue to work closely with the FDA to provide them with the additional information they requested, including data supporting the label claims related to Oxycodone ER’s abuse-deterrent properties,” ​said Odidi.

Regulatory history

Rexista is an oxycodone hydrochloride extended release opiate analgesic designed to treat patients requiring long-term pain relief.

Intellipharmaceutics submitted its new drug application (NDA) for Rexista on February 2, 2017.

On June 26, the FDA’s Anaesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted against the approval of Rexista, 22 to 1.

A majority of members said Intellipharmaceutics had not demonstrated Rexista can deter abuse via intravenous injection.

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...